NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022-Reference-Cited by-同舟云学术

NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022

Published:2022-06 Issue:6 Volume:20 Page:622-634
ISSN:1540-1405
Container-title:Journal of the National Comprehensive Cancer Network
language:
Short-container-title:

Author:

Wierda William G.¹,Brown Jennifer²,Abramson Jeremy S.³,Awan Farrukh⁴,Bilgrami Syed F.⁵,Bociek Greg⁶,Brander Danielle⁷,Chanan-Khan Asher A.⁸,Coutre Steve E.⁹,Davis Randall S.¹⁰,Eradat Herbert¹¹,Fletcher Christopher D.¹²,Gaballa Sameh¹³,Ghobadi Armin¹⁴,Hamid Muhammad Saad¹⁵,Hernandez-Ilizaliturri Francisco¹⁶,Hill Brian¹⁷,Kaesberg Paul¹⁸,Kamdar Manali¹⁹,Kaplan Lawrence D.²⁰,Khan Nadia²¹,Kipps Thomas J.²²,Ma Shuo²³,Mato Anthony²⁴,Mosse Claudio²⁵,Schuster Stephen²⁶,Siddiqi Tanya²⁷,Stephens Deborah M.²⁸,Ujjani Chaitra²⁹,Wagner-Johnston Nina³⁰,Woyach Jennifer A.³¹,Ye J. Christine³²,Dwyer Mary A.³³,Sundar Hema³³

Affiliation:

1. 1The University of Texas MD Anderson Cancer Center;

2. 2Dana-Farber/Brigham and Women's Cancer Center;

3. 3Massachusetts General Hospital Cancer Center;

4. 4UT Southwestern Simmons Comprehensive Cancer Center;

5. 5Yale Cancer Center/Smilow Cancer Hospital;

6. 6Fred & Pamela Buffett Cancer Center;

7. 7Duke Cancer Institute;

8. 8Mayo Clinic Cancer Center;

9. 9Stanford Cancer Institute;

10. 10O'Neal Comprehensive Cancer Center at UAB;

11. 11UCLA Jonsson Comprehensive Cancer Center;

12. 12University of Wisconsin Carbone Cancer Center;

13. 13Moffitt Cancer Center;

14. 14Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

15. 15St. Jude Children's Research Hospital/The University of Tennessee Health Science Center;

16. 16Roswell Park Comprehensive Cancer Center;

17. 17Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

18. 18UC Davis Comprehensive Cancer Center;

19. 19University of Colorado Cancer Center;

20. 20UCSF Helen Diller Family Comprehensive Cancer Center;

21. 21Fox Chase Cancer Center;

22. 22UC San Diego Moores Cancer Center;

23. 23Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

24. 24Memorial Sloan Kettering Cancer Center;

25. 25Vanderbilt-Ingram Cancer Center;

26. 26Abramson Cancer Center at the University of Pennsylvania;

27. 27City of Hope National Medical Center;

28. 28Huntsman Cancer Institute at the University of Utah;

29. 29Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;

30. 30The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

31. 31The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

32. 32University of Michigan Rogel Cancer Center; and

33. 33National Comprehensive Cancer Network.

Abstract

The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton’s tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors has emerged as an effective chemotherapy-free option for patients with previously untreated or relapsed/refractory CLL/SLL. Undetectable minimal residual disease after the end of treatment is emerging as an important predictor of progression-free and overall survival for patients treated with fixed-duration BCL-2 inhibitor-based treatment. These NCCN Guidelines Insights discuss the updates to the NCCN Guidelines for CLL/SLL specific to the use of chemotherapy-free treatment options for patients with treatment-naïve and relapsed/refractory disease.

Publisher

Harborside Press, LLC

Subject

Oncology

Link

https://jnccn.org/downloadpdf/journals/jnccn/20/6/article-p622.xml

Reference136 articles.

1. Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion;Tam;Haematologica,2020

2. Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion;Tam;Haematologica,2020

3. Safety of venetoclax rapid dose escalation in CLL patients previously treated with B-cell receptor signaling antagonists;Koenig;Blood Adv,2020

4. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study;Wierda;J Clin Oncol,2021

5. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study;Ahn;Blood,2018

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and validation of a nomogram for individualizing fall risk in patients with hematologic malignancies;Geriatric Nursing;2024-11

2. Radiomic prediction for durable response to high‐dose methotrexate‐based chemotherapy in primary central nervous system lymphoma;Cancer Medicine;2024-09

3. Simultaneous occurrence of papillary thyroid carcinoma, medullary thyroid carcinoma, and lymphoma: A case report;Medicine;2024-08-16

4. IgG testing, immunoglobulin replacement therapy, and infection outcomes in patients with CLL or NHL: real-world evidence;Blood Advances;2024-08-14

5. Knowledge, skills, and confidence gaps impacting treatment decision making in relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma: a quantitative survey study in France, Germany, and the United States;BMC Cancer;2024-08-13